SynsoryBio GTM brain

category

market profile

• text: Restricting potent biologic activity to diseased tissue could expand the therapeutic window; clinical benefit remains unproven in the public materials reviewed.
• text: Antibody masking and conditional activation are active areas of oncology drug development, with multiple companies pursuing different approaches.

personas

• title: Biopharma business development and licensing lead
  pains:

  • Needs differentiated therapeutic platforms for assets limited by systemic toxicity
  • Must evaluate IP, research data and deal terms before committing to a collaboration
• title: Oncology R&D leader
  pains:

  • Potent treatments can have dose-limiting activity outside diseased tissue
  • Needs evidence that conditional activation is selective and preserves efficacy
• title: Protein engineering and translational research lead
  pains:

  • Must identify reliable disease markers and suitable activation thresholds
  • Needs a switch compatible with the protein and disease biology

icp

• text: Potential collaborators are biotech and pharmaceutical companies developing potent protein drugs for oncology or autoimmune disease; commercial partnering is inferred, not confirmed.
• text: Research groups with protein engineering and disease marker expertise are plausible scientific partners, although account size and stage are undisclosed.

message pillars

• text: Build conditional logic into therapeutic proteins.
• text: Use an if-then design concept to frame molecular response.
• text: Focus on engineered protein drugs.

objections

• objection: Is there clinical evidence of safety and efficacy?
  response: Public material describes potential rather than clinical proof; request program-specific preclinical and clinical data.
• objection: Will the mechanism distinguish diseased from healthy tissue for our target?
  response: Assess the marker, activation threshold and off-target activity for each intended molecule and indication.
• objection: How is this different from masked biologics already in development?
  response: Compare mechanism, evidence, IP and development stage with established conditional activation programs.

competitors

• name: CytomX Therapeutics
  why: Develops conditionally activated Probody cancer therapeutics.
• name: Xilio Therapeutics
  why: Develops tumor-activated immunotherapies, including an IL-12 program.
• name: Janux Therapeutics
  why: Pursues conditional activation approaches in oncology.

influencers

• name: Nathan Tague
  url: https://startupintros.com/people/nathan-tague
  why: SynsoryBio co-founder working on conditional protein therapeutics.

keywords

• conditionally activated protein therapeutics
• tumor activated biologics
• disease sensing protein drugs
• conditional immunotherapy platform
• therapeutic window oncology
• protein engineering immunotherapy

voice

• Scientific
• Concise
• Mechanism-focused

signals

• text: An oncology developer is looking to improve a potent drug's therapeutic window or reduce systemic exposure.
• text: A biopharma group is evaluating conditional activation or tumor-localized immunotherapy partnerships.

pricing

motion

confidence

Founders

• name: Elliot Tague
  title: Founder
  role: Founder
  bio: I am a PhD and inventor in the fields of synthetic biology and protein engineering. I got my PhD from Boston University, spent time as a visiting graduate student in George Church's lab at Harvard, and worked in various biotech startups
• name: Nathan Tague
  title: Founder
  role: Founder
  bio: I’m a co-founder of SynsoryBio, where we are creating therapeutics that sense-and-respond to disease. I have a background in synthetic biology and protein engineering with a PhD in Biomedical Engineering.